Evan Feinberg, Genesis Therapeutics CEO
Andreessen Horowitz-backed startup lands $200M for AI-based drug discovery
Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200 million in Series B financing — one of the largest rounds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.